05.07.10
Meda has acquired exclusive rights to flupirtine for the treatment of fibromyalgia from Adeona Pharmaceuticals, in the U.S., Canada and Japan. Meda will take over full responsibility for development and commercialization of the drug, which is currently in Phase II development for fibromyalgia. Under the agreement, Adeona will receive an up front payment, milestone payments upon FDA acceptance and approval of the NDA, and royalties on sales.
“We are very pleased to collaborate with Adeona in the development of flupirtine for fibromyalgia, a therapeutic area with a large unmet medical need. Flupirtine has the potential to have better efficacy and safety than current treatments. Additionally, flupirtine has displayed good tolerability during all the years it has been used for the treatment of acute and chronic pain,” said Anders Lönner, chief executive officer of Meda.
“We are very pleased to collaborate with Adeona in the development of flupirtine for fibromyalgia, a therapeutic area with a large unmet medical need. Flupirtine has the potential to have better efficacy and safety than current treatments. Additionally, flupirtine has displayed good tolerability during all the years it has been used for the treatment of acute and chronic pain,” said Anders Lönner, chief executive officer of Meda.